GlassScriptPhysician profile
Ewa M Slaby
NPI 1407420581
$3,248.63
in general payments reported to CMS, 2019-2025
27 companies · $571 in 2025
The $571 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $498 · 2022: $885 · 2023: $631 · 2024: $663 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,849 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,849.05 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,172.92 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $480.76 | 2021-2023 | Injectafer |
| Lilly USA, LLC | $294.07 | 2021-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $226.79 | 2023-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $158.47 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Exact Sciences Corporation | $103.36 | 2023-2024 | Cologuard Collection Kit |
| Myriad Women'S Health, INC. | $84.05 | 2023 | Myrisk |
| Pfizer INC. | $82.13 | 2022-2025 | |
| Glaxosmithkline, LLC. | $79.06 | 2021-2025 | Shingrix, Arexvy |
| Amgen INC. | $65.56 | 2021-2025 | Krystexxa, Otezla, Repatha |
| Inspire Medical Systems, INC. | $62.86 | 2024-2025 | Inspire |
| Abbvie INC. | $55.15 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.34 | 2022-2024 | Jardiance |
| Mannkind Corporation | $44.03 | 2021-2022 | |
| Amarin Pharma, INC. | $39.91 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $35.26 | 2021 | |
| Merck Sharp & Dohme LLC | $32.25 | 2022-2025 | Capvaxive |
| Sanofi-Aventis U.S. LLC | $30.69 | 2022-2024 | |
| Dexcom, INC. | $29.53 | 2024 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $27.64 | 2023 | |
| Currax Pharmaceuticals LLC | $17.66 | 2023 | Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.72 | 2024 | Xifaxan |
| Esperion Therapeutics, INC. | $14.67 | 2021 | |
| Intra-Sana Laboratories | $14.54 | 2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Corcept Therapeutics | $13.88 | 2024 | Korlym |
| Arbor Pharmaceuticals, INC. | $13.23 | 2021 | |
| Althera Pharmaceuticals LLC | $8.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ewa Slaby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.